BeamWorks, Inc. appears in FDA records at a Daegu, Republic of Korea address, with MinGi Seo listed as regulatory affairs contact on a 2026 clearance letter and Nayeon Oh listed as applicant contact in the 510(k) database entry. The public documents document two 510(k) submissions for the same device name, CadAI-B Dx, both decided substantially equivalent. Company-level descriptions of the CadAI product line come from BeamWorks’ own website, which identifies Won Hwa Kim and Jaeil Kim as CEOs. [2][3][4]

Two 510(k) records for CadAI-B Dx

The supplied portfolio snapshot contains one linked record: K263749, CadAI-B Dx, product code QDQ, received October 16, 2026 and decided November 6, 2026 as substantially equivalent under a Special clearance type. The snapshot’s decision counts show one SESE decision across the collection and one SESE decision within the single-record sample. These counts describe the supplied filings as of the snapshot date, not total company sales, total portfolio or safety performance. [1]

A separate FDA record covers K260086, also named CadAI-B Dx, with a Traditional 510(k) type, a decision date of August 12, 2026 and a substantially equivalent decision. The database entry lists the applicant as BeamWorks, Inc. at the Daegu address, with Nayeon Oh as applicant contact and MinGi Seo as correspondent contact. The review panel and medical specialty are radiology. [3]

Predicate and review basis

The K260086 clearance letter, addressed to MinGi Seo as regulatory affairs manager, states that performance data demonstrated CadAI-B Dx performs substantially equivalently to the legally marketed predicate device BU-CAD (K210670) without raising new questions of safety or effectiveness. The letter identifies the regulation as 21 CFR 892.2090, radiological computer-assisted detection and diagnosis software, Class II, product code QDQ. [2]

The same letter records the device as dated and received July 13, 2026, while the database entry for K260086 shows a received date of January 12, 2026 and a decision date of August 12, 2026. The public documents do not reconcile these dates, so the submission timeline for K260086 remains inconsistent across documents. [2][3]

Product line as described by the company

BeamWorks’ website presents the CadAI series as on-device AI built for the pace of clinical care, describing CadAI-B as an AI ultrasound breast diagnostic solution with FDA 510(k) clearance and CadAI-T as a real-time AI ultrasound thyroid diagnostic solution. The site also references an MFDS medical device manufacturing approval. These are company-published descriptions; the public documents do not establish commercial availability, customers or clinical performance. [4][5]

The site lists BeamWorks Inc. with CEOs Won Hwa Kim and Jaeil Kim, a Daegu location matching the FDA filing address, telephone and fax numbers, and an email address. The FDA filing address is a regulatory correspondence address and is not treated here as a verified headquarters. No parent company, brand owner or corporate ownership structure is verified in the public documents. [4][6]

Named clinical study and conference abstract

A ClinicalTrials.gov record, NCT07287111, is titled “Effectiveness of CadAI-B Dx for Decision Support in Breast Ultrasound.” The supplied excerpt contains only site navigation and policy text, so the study’s design, status, sites and results are unknown from these sources. [7]

A 2025 ASCO Annual Meeting abstract in the Journal of Clinical Oncology is titled “Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study,” with Won Hwa Kim and Jaeil Kim among the listed authors. The supplied excerpt does not link the abstract to CadAI-B Dx or report outcomes, so any connection to the cleared device is unverified. [8]